All In Biotech

Drug Trial Radar · NCT07912996

Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes

A Phase 2b, Randomized, Double-Blind, Active-Control, Parallel-Group Study to Evaluate the Safety and Efficacy of GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to compare the study drug GS-1179, versus valacyclovir (VACV) in herpes simplex virus type 2 (HSV-2) seropositive participants with recurrent genital herpes. The primary objective of this study are to evaluate the safety and tolerability of GS-1179 versus VACV and to evaluate the antiviral effect of GS-1179 versus VACV.

Conditions

  • HSV-2 Infection

Interventions

  • GS-1179Drug

    Administered orally

  • GS-1179 PTMDrug

    Administered orally

  • ValacyclovirDrug

    Administered orally

  • Valacyclovir PTMDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Adverse Events (AEs)Time frame: Enrollment up to 92 days
  2. Percentage of Participants Experiencing Premature Study-Dug Discontinuation due to AEsTime frame: Enrollment up to 92 days
  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to 92 days
  4. Herpes Simplex Virus Type 2 (HSV-2) Shedding Rate During the Swabbing PeriodTime frame: Day 8 to Day 38

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.